
I have a new book. Inessential Pharmacology: A Frontier Psychiatrists' Guide to Understanding Psychiatric Medications a.co/d/0cXDUkdh

Proficimus More Irretenti. 🇮🇱 iapps.courts.state.ny.us/nys…

I have a new book. Inessential Pharmacology: A Frontier Psychiatrists' Guide to Understanding Psychiatric Medications a.co/d/0cXDUkdh

Two Radial Co-Founders Depart Owen Muir and Carlene MacMillan are transitioning out of their roles as Chief Scientific Officer and Chief Product Officer, respectively, at Radial, the company has confirmed to Psychedelic Alpha. The pair were two of four co-founders of the interventional psychiatry network, which launched with $50M in funding last December and acquired Mindful Health Solutions earlier this year. The group of clinics is expected to be among the first to offer psychedelics, if approved, and entered into a strategic collaboration with Compass Pathways in January. For now, the company’s Chief Medical Officer, Tobias Marton, “will oversee all clinical and research-based work moving forward”, Radial Chief Executive Officer John Capecelatro told us. Read more on our website: psychedelicalpha.com/news/p%…

Living it up by talking with people with lived experience at the Society for Neuroscience Annual Meeting! What is lived experience? It is the firsthand knowledge and understanding people gain from living with a medical condition, neurodivergence, disability, mental health crisis, or being a caregiver or relative. Thanks for your efforts to bridge understandings, Jennifer French, Ed Twomey, Devin Effinger, Brandon Staglin, Rachel Wurzman, Uma Chatterjee, and the many who shared their insights on and off the stages!

After childbirth, Lindsay Clancy stopped sleeping, and each new prescription made it worse. We follow her journey through the newly released malpractice flings in the Carlat Psychiatry Podcast: thecarlatreport.com/blogs/2-… Plus an update on a new risk with GLP-1 agonists.

It was a dark and stormy night, yet the end of the tunnel was bright! No I was not hit by a train, that would be beyond a freight. Rapid Acting Mental Health Treatment NYC is in the books. Inspired by the existing and emerging treatment options. Transcranial Magnetic Stimulation (TMS) has been FDA-approved for almost two decades, and with the development of Magnus's repetitive TMS (rTMS) and Ampa's accelerated TMS (aTMS), it has become a faster-acting treatment for depression over time. Brain-computer interfaces are also in the works to treat depression without drugs, with discussions of Abbott | Neuromodulation's TRANSCEND study and Motif Neurotech's RESONATE clinical trial brochure on display. Thus, if the field is left to our own devices, there is a growing array of devices. Further, on Kalshi, about half of people think psychedelics will be FDA-approved for a mental health indication in 2027. To add more light to the mind-expanding situation, some of us even received @ScottMuirMD bobbleheads!

A Surprise Pick: Mark Cuban’s Company to Develop Ibogaine for PTSD with ARPA-H Backing Read more: psychedelicalpha.com/news/br…

Hope to see you this Thursday in New York City. It's called Rapid Acting Mental Health, with updates on new devices in psychiatry: eventbrite.com/e/ramht-2026-… (and Kellie Aiken will be there, interviewing a patient)

Ibogaine’s Impact Lasted A Year: How Should We Interpret It? via @forbes forbes.com/sites/robertglatt… @StanfordMed @ScottMuirMD @ Dr. Cammie Rolle @ Dr. Glen Brooks


Today, I'm happy to share one of my more important contributions to science, the favorable durability data from the @BrainsWay SWIFT trial. Proud to be a co-author of this important piece of science. Durable remission of depression is in the standard of care. #brainmedicine

“The reason I'm personally tackling ibogaine is that it’s the most difficult. I have no doubt that other psychedelics will get through the finish line, but an oneirogenic like ibogaine, that people have died from, is very challenging, and it will need a lot of cooperation, collaboration, a lot of work.” Al Bugazia, Deputy Director, Proactive Health, ARPA-H, speaking at The Psychedelic Healthcare Forum.

Horizons Dispatch: The Plasticity of Psychiatry III thefrontierpsychiatrists.sub…

“Expect enthusiasm from patients and clinicians on day one, and expect payers not to be ready. With Spravato, some payers built a prior auth process quickly and others took much longer. For the first few weeks, whoever answered the phone, person or chatbot, often didn’t know how to help. That happens with most new drugs, and psychedelics will be no exception.” Carlene MacMillan spoke with us for the seventh Issue of The Psychedelic Practitioner, which focuses on psychedelic preparedness (systems). Read now on our website: psychedelicalpha.com/news/th…


open.spotify.com/album/6U4ld… the last full length album recorded at tiny telephone in the Mission District before the pandemic shut everything down.
